Skip to main content
Medico Intercontinental Limited logo

Medico Intercontinental Limited — Investor Relations & Filings

Ticker · 539938 ISIN · INE858Q01019 LEI · 984500F5C7406A466E68 BSE.NS Wholesale and retail trade
Filings indexed 5 across all filing types
Latest filing 2026-05-23 Earnings Release
Country IN India
Listing BSE.NS 539938

About Medico Intercontinental Limited

https://medicointercontinental.com/

Medico Intercontinental Limited specializes in the marketing and distribution of a broad spectrum of pharmaceutical formulations. The company’s product portfolio encompasses various therapeutic segments, including anti-infectives, antibiotics, analgesics, anti-inflammatory agents, and gastrointestinal medications. Additionally, it provides nutritional supplements and health-related formulations. The business model focuses on sourcing and distributing high-quality medicinal products through strategic collaborations and contract manufacturing partnerships. By maintaining a robust supply chain and adhering to quality assurance standards, the company ensures the availability of essential healthcare products. Its operations are centered on meeting diverse medical requirements through a comprehensive range of generic and branded formulations designed for both acute and chronic therapeutic applications.

Recent filings

Filing Released Lang Actions
Newspaper Publication
Earnings Release Classification · 78% confidence The document is a formal stock‐exchange disclosure from Medico Intercontinental Limited notifying the listing compliance departments of BSE and CSE that its audited financial results (Standalone & Consolidated) for the quarter and year ended March 31, 2026, have been approved by the Board and published in newspapers. It encloses the newspaper clipping of those results. This matches the definition of an Earnings Release (initial announcement of quarterly/periodical financial results). Therefore, the correct classification is ER. FY 2026
2026-05-23 English
Intimation of Re-appointment of an Internal Auditors.
Regulatory Filings Classification · 90% confidence The document is an intimation to stock exchanges under SEBI Listing Obligations (Regulation 30) announcing the appointment of an internal auditor. It is a mandatory regulatory disclosure rather than a full financial report, management discussion, or earnings release. It does not present financial data or detailed report content, but compliance information under listing regulations. This aligns with the Regulatory Filings (RNS) category for general exchange disclosures.
2026-05-22 English
Results for the quarter and financial year ended March 31, 2026
Interim / Quarterly Report Classification · 75% confidence The document is the official SEBI Regulation 30 & 33 Board meeting outcome announcing and attaching the Standalone and Consolidated Audited Financial Results and the full Independent Auditor’s Report for the quarter and year ended March 31, 2026. It contains substantive financial statements (P&L, Balance Sheet, Cash Flows) and the auditor’s opinion—not just key highlights—so it is a full financial report rather than a brief earnings release or mere publication notice. It is not a full corporate annual report (10-K) or a proxy/solicitation statement, but a comprehensive periodical financial report. Therefore, it fits the Interim/Quarterly Report category (IR). FY 2026
2026-05-22 English
Outcome of Board meeting dated May 22, 2026.
Interim / Quarterly Report Classification · 91% confidence The document is Medico Intercontinental’s formal board meeting outcome to the stock exchanges under SEBI LODR Reg 30/33, enclosing the Audited Standalone Financial Results for Q4 and the full year ended March 31, 2026 along with the Independent Auditor’s Report and detailed P&L, balance sheet and cash flow statements. It is not a short release (“earnings release”), nor a full “Annual Report” with MD&A, nor merely a publication announcement. It contains comprehensive financial statements for the period, matching the definition of an Interim/Quarterly Report filing under our taxonomy. FY 2026
2026-05-22 English
Medico Intercontinental Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve and take on record ....
Regulatory Filings Classification · 92% confidence The document is a formal notice to the stock exchange about scheduling a Board of Directors meeting to consider and approve audited financial results. It does not contain any actual financial statements or results, nor does it announce changes in board composition or executive management. It is not the report itself, nor a proxy or voting results document. It is a regulatory compliance announcement under SEBI listing rules, fitting the general “Regulatory Filings” category as a routine exchange notification.
2026-05-14 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.